Clinical trials: Vitamin K
Stroke
Study of the Follow-up of Stroke Treated With Anticoagulants
Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap).
- Trial name
- AOD (NCT03292575)
- Testing
- Anticoagulants
- Where
- France
- Volunteers
- 441 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Hepatocellular Carcinoma
Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC
The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate…
- Trial name
- NCT03047603
- Testing
- PIVKA-II
- Where
- China
- Volunteers
- 4,005 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Anticoagulant-induced Bleeding
DOAC Versus VKA After Cardiac Surgery
Postoperative management of oral anticoagulation is a frequent preoccupation in cardiac surgery, concerning about half of patients.
- Trial name
- DOAC/VKA (NCT04002011)
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Sponsor
- Laval University
Atrial Fibrillation
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
This is a national, multi-center, prospective study to evaluate the safety of Edoxaban in patients diagnosed with AF who are currently using Edoxaban for stroke prevention.
- Trial name
- ETAF-TR (NCT04594915)
- Testing
- Edoxaban
- Where
- 45 sites in Turkey (Türkiye)
- Volunteers
- 1,053 people
- Sponsor
- Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Coagulation Factor Deficiency, Coagulopathy, Consumption
Effect of Vitamin K in Critically Ill Patients
Critically ill patients with spontaneously prolonged pro-thrombin time, where administration of intravenous administration of phytomenadione (vitamin K) has been ordered by the treating physician will be identified.
- Conditions
- Coagulation Factor Deficiency, Coagulopathy, Consumption, Vitamin K Deficiency
- Trial name
- VITAKOAG (NCT03782025)
- Testing
- Phytomenadione
- Where
- 2 sites in Sweden
- Volunteers
- 52 people
- Sponsor
- Region Skane
Atrial Fibrillation
Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Study objective is to demonstrate that anticoagulation with the direct factor Xa inhibitor apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing catheter ablation of non-valvular AF in the…
- Trial name
- AXAFA (NCT02227550)
- Testing
- Vitamin K antagonist, Apixaban
- Where
- 13 sites in United States, Austria and 7 more
- Volunteers
- 676 people
- Sponsor
- Atrial Fibrillation Network
Covid19
Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). While the majority of people recover after mild symptoms, a portion of COVID-19 patients develops respiratory…
- Trial name
- KOVIT (NCT04770740)
- Testing
- Vitamin K2 in the form of Menaquinone-7 (MK-7)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Canisius-Wilhelmina Hospital
Anticoagulated Patients
Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy
The purpose of this study is to determine whether the new algorithm is safety and effective in proposing the dosage and the timing of oral anticoagulant therapy.
- Trial name
- NCT01392040
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University Of Perugia
Atrial Fibrillation, Atrial Flutter
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-AF (NCT03129490)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 38 sites in Denmark
- Volunteers
- 11,000 people
- Sponsor
- Herlev and Gentofte Hospital
Atrial Fibrillation
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting.
- Trial name
- ENTRUST-AF-PCI (NCT02866175)
- Testing
- Edoxaban, Clopidogrel, Prasugrel
- Where
- 200 sites in Austria, Belgium and 16 more
- Volunteers
- 1,506 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Cardiovascular Disease
Predictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death
The overall objective of this research proposal is to determine whether the predictive value of using plasma concentrations of selected nutrient biomarkers of food intake determined using a single plasma sample either alone or in…
- Trial name
- WHI (NCT01864122)
- Where
- United States
- Volunteers
- 2,448 people, healthy volunteers welcome
- Sponsor
- Tufts University
Neurocognitive Disorders
VItamin K Inhibition and NeurocoGnition (VIKING)
The primary objective of this study is to determine whether patients usually taking Vitamin K Antagonists (VKAs) exhibit a poorer global cognitive performance than control patients (matched on age, gender and indication for…
- Trial name
- VIKING (NCT03276377)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding
Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients
The goal of this randomized controlled clinical trial is to evaluate the efficacy of Tranexamic acid and vitamin K injection versus placebo in control of upper gastrointestinal bleeding (UGIB) in Egyptian cirrhotic patients.
- Conditions
- Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding, Cirrhosis
- Trial name
- NCT06881628
- Testing
- Tranexamic Acid and vitamin K
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Tanta University
Healthy Women, Osteocalcin
Jarlsberg Cheese Compared to Camembert Cheese
The study objective consists of the following three aims: 1. To compare the effect of daily intake of Jarlsberg cheese and Camembert cheese in change of the Osteocalcin level in healthy women after 6 weeks. 2.
- Trial name
- NCT04189796
- Testing
- Cheese
- Where
- Norway
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Prof Stig Larsen
Head Trauma, Head Injury
Delayed IntraCranial Hemorrhage in Oral AntiCoagulant Treated Patients With Mild Traumatic Brain Injury
As a low quality, weak recommendation, it is part of the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults, that patient with a GCS of 14-15 and anticoagulation therapy and a…
- Conditions
- Head Trauma, Head Injury, Delirium, Thrombosis
- Trial name
- dICH-OAC (NCT07195760)
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Bispebjerg Hospital
Burns
Comparison of Vitamin K Doses in Patients With Larger Burn Injuries
The use of Vitamin K in treating bleeding diatheses is well documented and accepted as standard of care, as is the effect of Vitamin K on calcium and bone metabolism.
- Trial name
- VITK (NCT03941535)
- Testing
- Vitamin K
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Joseph M. Still Research Foundation, Inc.
Intracranial Hemorrhages
International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage
Intracerebral haemorrhage (ICH) is the most feared complication in patients on vitamin K antagonists (VKA). VKA related ICH occurs 8-10 times more frequently and the mortality is 2 times higher than in non-anticoagulated…
- Trial name
- INCH (NCT00928915)
- Testing
- Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Heidelberg University
Persistent or Permanent Nonvalvular Atrial Fibrillation
Long-term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and…
- Trial name
- NCT00645853
- Testing
- AZD0837, VKA INR 2-3
- Volunteers
- 523 people
- Sponsor
- AstraZeneca